GTC Biotherapeutics (fka GTCB)

[keitern]

I suppose I shouldn't speculate, but that IS what it feels like to me. Some kind of valuation based on average closing share price to facilitate an offering, a partnership, or a deal of some sort. Someone has shares to burn. The story is to good here and the valuation (EV about 60M after all that's gone into this company) too low to warrant this kind of aggressive knock-down day after day.

Anyway, it does seem unlikely and maybe we will see some changes in ownership, short interest or both soon that will give us real insight.